Obinutuzumab vs Tacrolimus in Primary Membranous Nephropathy: MAJESTY Phase 3 Results

The MAJESTY phase 3 trial demonstrates that obinutuzumab is significantly more effective than tacrolimus in achieving complete remission at 104 weeks for adults with primary membranous nephropathy, with a comparable safety profile.

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.